Bridging Study for Killed Oral Cholera Vaccine in Ethiopia

Status Completed

Clinical Trial Summary

This is a randomized, double blind, placebo controlled trial to confirm the safety and determine the immune response of the killed oral cholera vaccine in healthy adults and children in Ethiopia.

Clinical Trial Description

This study serves as a bridging trial to evaluate the safety and immunogenicity of a two dose regimen of the WC-OCV (Shanchol®) in Ethiopian population. In order to assess whether the bivalent killed oral cholera vaccine may be used safely among those who are most at risk for cholera, we need to determine the safety and immunogenicity of the killed oral cholera vaccine. The vaccine was evaluated in a large number of human subjects in India Vietnam, and Bangladesh, in which it has demonstrated safety, immunogenicity, and clinical protective efficacy. Though we do not expect the vaccine to act differently in the Ethiopian population, we aim to confirm our presumptive understanding that two doses of WC-OCV is safe and immunogenic in healthy volunteers at one year and above (exclusive of pregnant women). Findings from this study can pave the way for the possible use of the killed whole cell oral cholera vaccine in both endemic and outbreak settings at a larger scale. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01524640
Study type	Interventional
Source	International Vaccine Institute
Contact
Status	Completed
Phase	Phase 4
Start date	December 2012
Completion date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01895855` - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera	Phase 3
Completed	`NCT01339845` - Introduction of Cholera Vaccine in Bangladesh	N/A
Recruiting	`NCT05829772` - Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
Completed	`NCT04760236` - Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™	Phase 3
Recruiting	`NCT04326478` - Single Dose Azithromycin to Prevent Cholera in Children	Phase 2
Recruiting	`NCT06104345` - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines	Phase 4
Completed	`NCT02928341` - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo	N/A
Completed	`NCT02864433` - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Recruiting	`NCT06003816` - Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)	N/A
Not yet recruiting	`NCT05771779` - Co-administration Study of OCV, TCV and MR	Phase 3
Not yet recruiting	`NCT06455852` - Correlates of Protection for Cholera	N/A
Completed	`NCT04150250` - Cholera Anti-Secretory Treatment Trial	Phase 2
Terminated	`NCT00624975` - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants	Phase 2
Completed	`NCT00226616` - Zinc Supplementation in Cholera Patients	Phase 3
Completed	`NCT03373669` - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine	Phase 4
Completed	`NCT02094586` - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults	Phase 3
Completed	`NCT02100631` - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults	Phase 3
Completed	`NCT01823939` - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera	Phase 1
Completed	`NCT01365442` - Pilot Introduction of Oral Cholera Vaccine in Orissa, India	N/A
Completed	`NCT00128011` - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine	Phase 2